Has Ashwini Gore, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,579,669 in general payments to Ashwini Gore, MD across 1,600 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashwini Gore, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashwini Gore, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashwini Gore, MD

Endocrinology, Diabetes & Metabolism · Macon, GANPI 1457373565

Payments from drug & device makers

$2,579,669in general payments, 2019–2025

Across 1,600 payments — averaging $1612.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$828K
Boehringer Ingelheim International GmbH$289K
Boehringer Ingelheim Pharma GmbH & Co.kg$274K
Astrazeneca UK Limited$228K
Bayer$200K
Boehringer Ingelheim$200K
plus $560K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	30	$828,187
Boehringer Ingelheim International GmbH	119	$289,380
Boehringer Ingelheim Pharma GmbH & Co.kg	13	$273,574
Astrazeneca UK Limited	5	$227,767
Bayer	89	$200,286
Boehringer Ingelheim	63	$200,238
Alnylam Pharmaceuticals Inc.	385	$160,223
AstraZeneca(2 entities)	55	$129,271
Biogen	1	$107,849
Pfizer	20	$83,284
Amgen(2 entities)	98	$48,902
Novo Nordisk	112	$7,303
Merck	20	$6,681
Johnson & Johnson	15	$2,729
Tandem Diabetes Care, Inc.	24	$1,777
Eli Lilly	1	$1,620
Lilly USA, LLC	95	$1,472
Sanofi-aventis U.S. LLC	51	$946
Corcept Therapeutics	45	$877
Xeris Pharmaceuticals, Inc.	22	$602
Insulet Corporation	20	$464
Amneal Pharmaceuticals LLC	26	$438
Radius Health, Inc.	20	$429
Dexcom, Inc.	26	$387
Medtronic(2 entities)	15	$360
Bigfoot Biomedical Inc	6	$354
Valeritas, Inc.	19	$336
Abbott	19	$288
Zealand Pharma US, Inc.	18	$273
Antares Pharma, Inc.	16	$256
AbbVie	18	$251
Amarin Pharma, Inc.	13	$227
Clarus Therapeutics Inc.	10	$194
Mannkind Corporation	7	$187
BETA Bionics, Inc.	6	$185
Cequr Corporation	4	$175
Vivus LLC	4	$154
Senseonics, Incorporated	7	$146
Madrigal Pharmaceuticals	6	$136
IBSA Pharma Inc.	8	$131
Ascensia Diabetes Care US Inc.	6	$124
Kyowa Kirin, Inc.	5	$111
Eisai Inc.	1	$109
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$107
Esperion Therapeutics, Inc.	6	$102
Ascendis Pharma Endocrinology Inc	5	$101
BD	5	$86
Embecta Corp.	4	$74
Companion Medical, Inc.	4	$71
Shire North American Group Inc	4	$48
Halozyme Inc	2	$42
Regeneron Healthcare Solutions, Inc.	3	$41
Verity Pharmaceuticals Inc.	2	$36
Tolmar, Inc.	2	$34
Sun Pharmaceutical Industries Inc.	2	$30
Endo Pharmaceuticals Inc.	2	$26
Chiesi USA, Inc.	1	$23
Amphastar Pharmaceuticals, Inc.	1	$22
Ipsen Biopharmaceuticals, Inc	1	$22
GSK	1	$21

How this compares

$2,579,669 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024

$126,141

Medicare patients

468

Services billed

6,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Macon

Thomas JonesMacon$4.8M
Barry JohnsMacon$495K
Bruce BodeAtlanta$18.3M
Gulliermo UmpierrezAtlanta$6.6M
John ReedRoswell$5.7M
Steven LeichterColumbus$3.1M
Jason BernerJasper$2.6M
Adeniyi OdugbesanLawrenceville$1.8M
David RobertsonAtlanta$1.7M
Thomas ZieglerAtlanta$1M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →